Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuchen Jiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Qing Yang(Guangzhou University of Chinese Medicine), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Lan(Chinese Academy of Medical Sciences & Peking Union Medical College), Beibei Yang(Fujian Medical University), Pei Wang(Nanchang University), Xuelian Chen(Chengdu Medical College), Xingyuan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Dawei Wu(Chinese PLA General Hospital), Dong Qu(Chinese Academy of Medical Sciences & Peking Union Medical College), Hong‐Tu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Weilong Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 218
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
|Science|2011|1.7k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k